The U.S. Food and Drug Administration's top vaccine official, Vinay Prasad, has left the agency after just three months as ...

The Food and Drug Administration’s polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of ...

WASHINGTON - It probably sits waiting, largely unnoticed, on the shelves of every smoke shop, convenience store and gas ...

Vinay Prasad, the top vaccine regulator and chief scientific officer at the Food and Drug Administration (FDA) and a critic of the agency’s COVID-19 policies, has departed after being on the job ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

Under the Inflation Reduction Act, medications with the same active ingredient will be treated as the same drug for price ...

Shares of drugmaker Sarepta Therapeutics surged in afterhours trading Monday after the company said it would resume shipping its gene therapy.

Arquitos Capital Management gained 13.1% in Q2 2025. Learn how they turned market uncertainty into opportunity with Liquidia ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

The Trump administration is inching closer to banning fluoride tablets and drops often prescribed to kids who don’t have ...

The FDA has decided not to approve glofitamab plus gemcitabine and oxaliplatin to treat certain patients with relapsed/refractory DLBCL.

Tummy bug testing outfit Genetic Signatures is honing its operations after finding its company-making US expansion was harder ...